(NASDAQ: NRXP) Nrx Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Nrx Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast NRXP's revenue for 2025 to be $646,177,715, with the lowest NRXP revenue forecast at $646,177,715, and the highest NRXP revenue forecast at $646,177,715.
In 2026, NRXP is forecast to generate $676,625,880 in revenue, with the lowest revenue forecast at $676,625,880 and the highest revenue forecast at $676,625,880.